• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
eric-francotte-master-of-chirality
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Discovery

Eric Francotte: Master of chirality

By
Catherine Hiller
Mar 03, 2015

We are a twisted species, and so are our molecules. Many organic molecules are not symmetrical: they bulge, lean, branch or twist to the left or the right. Nature generally makes only one form of the molecule, but laboratory synthesis for drug research frequently produces both left-handed and right-handed variants of the same molecule. These (usually manufactured) mirror images of each other are called enantiomers or isomers. One such chiral twin may be beneficial to humans, while the other is highly toxic. For instance, one form of thalidomide is a sedative and reduces morning sickness, while the other causes fetal deformities. So it is vital to separate enantiomers, but until 30 years ago, it was difficult to do so.

Enter NIBR’s Eric Francotte, Executive Director in Global Discovery Chemistry – and master of chirality. In the late 1980s, Francotte worked for the Novartis predecessor, Ciba-Geigy, in its Central Research Lab. He and his group began working on ways to separate enantiomers. “Our bodies are chiral,” he says. “Our biological receptors are chiral, so it’s natural that they respond best to one form of a molecule, where there’s better selectivity and more interaction. The drug is the key, the target is the lock, and one enantiomer better fits the target receptor.”

eric-francotte

“Thalidomide was the ‘big bang’ of chirality for the pharmaceutical industry,” Francotte says. “The undesirable isomer produced those terrible results. Then the whole pharmaceutical industry knew they would have to systematically separate drug stereoisomers and test them separately. There was no choice anymore.”

It was a great challenge. The breakthrough came when Francotte began using chiral materials in a chromatography column to discriminate between the two chiral forms of a molecule. He says, “To recognize chirality you need a chiral instrument.” Francotte found that materials based on cellulose and amylose could best distinguish between the isomers: the lefties, say, would stick to the material while the righties would not.

Our hands are familiar macro examples of chiral twins: indeed, the word “chiral” is derived from “cheir,” Greek for hand. To see how you react to molecules which are different only in orientation, you need go no further than your fruit bowl.  Molecules of the same chemical composition produce both the scent of lemon and the scent of orange.  They are naturally occurring chiral twins, and your nose, like a chromatography column, can easily distinguish between the two enantiomers.

Francotte describes enantioselective chromatography as being “at the interface of chemistry, separation sciences, and physics.” Today, his chromatography columns, continuously improved, have become ubiquitous throughout the industry. Novartis out-licenses them to other companies which commercialized the technology.  “I’m quite happy it has reached this level of usefulness,” Francotte says. A pioneer in the field of separations, in 2006, he edited Chirality in Drug Research, which has become the standard book on the subject. Because of the process that he helped develop, Francotte has contributed to Novartis drugs countering hypertension, asthma, and multiple sclerosis. He recently collaborated with a team of scientists from Singapore on an anti-malarial molecule. And he has the satisfaction of knowing that today all drug  manufacturers work to achieve enantiomic purity before their products hit the market.

As a boy growing up in Belgium, Francotte walked along the beach collecting seashells, noting that the spiral shells invariably twisted up and to the right. He went to college in Brussels and continued his chemistry studies at the University of Louvain, where he received a BS and PhD. He moved to Geneva for a postdoc, and his passion shifted from seashells to flowers, which, in Switzerland, are easier to find – and more interesting and delightful to smell. Francotte has a keen nose and at one point considered working for the perfume industry. Flowers, too, are often chiral, twisting in one direction only, as evidenced by gardenias, mandevillas, oleanders and some orchids. After inhaling their perfume, which in most cases consists of chiral molecules, Francotte takes exquisite photographs of the blossoms, adding to his impressive image collection of chiral objects, both natural and man-made.

Wherever he looks, it’s a world gone chiral.

Tags: 
Biomedical Research, Drug Discovery, Novartis Institutes for BioMedical Research, Scientific Research, Biomedical Science

Catherine Hiller

Catherine Hiller

has written 5 novels and a book of short stories that was praised by John Updike. She is an editor and a climate change activist who enjoys kayaking in the harbor near her house.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

RNA strand
Discovery

Take a visual tour of medicines that target RNA

A kidney patient is smiling at the camera
Discovery

New hope for treating inflammatory diseases of the kidney

2D rendering of kidneys
Discovery

Predictive analytics could bring medicines to patients faster

You are here

  1. Home ›
  2. Stories ›
  3. Discovery

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.